Partnering is part of our strategy to bring new and innovative products to patients in our regions.
We remain focused on building an increasingly diverse portfolio through investments in internal R&D, partnerships and strategic acquisitions.
Our broad geographic presence, strong manufacturing and commercial capabilities, deep knowledge of local markets and long-standing reputation makes us uniquely positioned to attract partners. This enables us to grow our portfolio and increase patients’ access to differentiated medicines across our markets, putting better health within reach, every day.
Contact us: https://www.hikma.com/contact/
Partnership highlights
Bio-Thera Solutions, Ltd.
Monoclonal Antibody
Boehringer Ingelheim
Respiratory Diseases
Celltrion
Biological, Oncology and Rheumatology
Junshi Biosciences
Innovative Anti-PD-1 Monoclonal Antibody
Vifor Pharma
Blood and blood-forming and anti-anemic
Newsroom
All news stories Latest partnership news
Featured
Hikma acquires the rights to a portfolio of Takeda brands for the MENA region
Press Release, Product 19 December 2024
- Hikma expands its agreement with AFT Pharmaceuticals for the commercialisation of injectable pain medication Combogesic® into the Saudi, Jordanian and Iraqi Markets Press Release, Business Development 12 February 2024 Hikma expands its agreement with AFT Pharmaceuticals for the commercialisation of injectable pain medication Combogesic® into the Saudi, Jordanian and Iraqi Markets
- Hikma and Guardant Health sign exclusive partnership agreement to bring transformative cancer diagnostic technology to the Middle East and North Africa Press Release, Business Development 08 January 2024 Hikma and Guardant Health sign exclusive partnership agreement to bring transformative cancer diagnostic technology to the Middle East and North Africa
- Hikma and CanariaBio sign exclusive licensing agreement to bring Oregovomab to the Middle East and North Africa Press Release, Product 10 October 2023 Hikma and CanariaBio sign exclusive licensing agreement to bring Oregovomab to the Middle East and North Africa
- Hikma and Cosmo partner on exclusive licensing agreement for Winlevi® (Clascoterone) for the Middle East and North Africa Press Release, Business Development 02 October 2023 Hikma and Cosmo partner on exclusive licensing agreement for Winlevi® (Clascoterone) for the Middle East and North Africa
Related content